For research use only. Not for therapeutic Use.
Frexalimab（Cat No.:I042097）is an investigational monoclonal antibody designed to target and block the immune checkpoint receptor LAG-3 (Lymphocyte Activation Gene-3). LAG-3 plays a role in suppressing immune responses, especially in the tumor microenvironment, allowing cancer cells to evade immune detection. By inhibiting LAG-3, frexalimab aims to enhance T-cell activity and improve the body’s immune response against tumors. It is being evaluated in clinical trials for various cancers, including melanoma and non-small cell lung cancer (NSCLC), to assess its safety, efficacy, and potential in combination with other immunotherapies.
| CAS Number | 2515463-86-0 |
| Purity | ≥95% |
